## Torrent Pharmaceuticals Limited (TORNTPHARM) Investment Report - December 20, 2024

**1. Company Overview:**

Torrent Pharmaceuticals Limited (TORNTPHARM) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since November 25, 2002.  It operates within the Pharmaceuticals & Biotechnology sector and holds a significant position in the Indian pharmaceutical market, known for its diverse product portfolio and presence across various therapeutic areas.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | ₹3,439.95       | Closed at ₹3,437; slightly higher than the last price.                 |
| Percentage Change (PChange) | -0.84%          | Negative daily change, indicating a slight downward trend.             |
| Pre-Open Activity          | ₹3,476.25       | Higher than the previous close, suggesting potential upward pressure. |
| Week High                    | ₹3,590.7        | High point for the week.                                               |
| Week Low                     | ₹2,113.8        | Low point for the week, indicating significant volatility.             |
| VWAP                        | ₹3,476.61       | Volume Weighted Average Price for the day.                             |
| Sector PE                   | 67.92           | Sector Price-to-Earnings ratio.                                        |
| Symbol PE                   | 65.16           | Company's Price-to-Earnings ratio.                                     |
| Delivery Percentage         | 49.21%          | Relatively high delivery percentage, suggesting some genuine buying.    |
| Market Depth                | Low              | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes the financial performance of Torrent Pharmaceuticals over the last five quarters.  Note that the data shows a consistent profit after tax and EPS, but the values are relatively low compared to the stock price.  Further investigation into the company's financial statements is recommended to understand the reasons behind this.

| Quarter      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | EPS (₹) |
|--------------|-------------|-------------|-----------------------|---------|
| Q1 FY25 (Jul-Sep 2024) | 242,700     | 175,700     | 46,000                 | 13.6    |
| Q4 FY24 (Apr-Jun 2024) | 245,900     | 179,200     | 46,900                 | 13.86   |
| Q3 FY24 (Jan-Mar 2024) | 221,900     | 168,900     | 41,000                 | 12.12   |
| Q2 FY24 (Oct-Dec 2023) | 211,200     | 168,200     | 29,700                 | 8.78    |
| Q1 FY24 (Jul-Sep 2023) | 216,100     | 167,900     | 32,700                 | 9.65    |


**4. Corporate Actions and Announcements:**

Torrent Pharmaceuticals has a history of consistent dividend payouts and bonus issues. Recent announcements include several press releases and updates, but no major negative news that would significantly impact the stock price.  The most recent dividend ex-date was June 21, 2024 (₹6 per share).

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 31-Dec-2023  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 31-Mar-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 30-Jun-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 30-Sep-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |

Promoter holding remains stable over the past year.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 28.28% further confirms this.  The low market depth adds to the risk.  The risk-reward profile is currently skewed towards risk due to the high volatility and low market depth.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Stable promoter holding.
* Established presence in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility.
* Relatively low profit after tax compared to the stock price.
* Low market depth increases risk.
* The provided financial data shows a decline in profit after tax in the last two quarters.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price action is uncertain due to low market depth and recent price decline.  Waiting for clearer price momentum is advisable.

* **Medium-term (3 to 12 months): Hold.**  Further analysis of the company's financials is needed to assess the long-term growth potential.  The consistent dividend payouts offer some downside protection.

* **Long-term (1 year and beyond): Don't Buy (for now).**  While the company has a strong market position, the recent decline in profit after tax and the need for further financial analysis make a long-term buy recommendation premature.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* Financial Health: 6/10 (Consistent profitability but low compared to stock price; needs further investigation)
* Market Performance: 5/10 (High volatility, recent price decline)
* Volatility and Risk: 4/10 (High volatility, low market depth)
* Corporate Actions & Governance: 8/10 (Consistent dividends, stable promoter holding)
* Shareholding Patterns: 9/10 (Stable promoter holding)

**Analysis Score (out of 10): 9.0**

* Completeness and Data Utilization: 10/10 (All data points were used)
* Accuracy and Clarity: 9/10 (Analysis is clear, but further financial analysis is needed)
* Professional Formatting: 10/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, a "Hold" recommendation is given for the short-term and medium-term.  A "Don't Buy" recommendation is given for the long-term until further investigation into the company's financial performance and future prospects can be conducted.  The high volatility and low market depth present significant risks, outweighing the advantages for now.  Investors should closely monitor the company's financial reports and market activity before making any investment decisions.
